Peripheral T-Cell Lymphoma (PTCL) Market is Dominated by the US, Says DelveInsight in Report Available at MarketPublishers.com

London, United Kingdom, September 29, 2017 --(PR.com)-- Lymphomas are blood cancers, which are broadly classified into Hodgkin’s and Non-Hodgkin’s lymphoma. Lymphoma occurs when cells of the immune system called lymphocytes grow and multiply uncontrollably. Cancerous lymphocytes can travel to other parts of the body; there are two main types of lymphocytes that can develop into lymphomas namely B-lymphocytes (B-cells) and T-lymphocytes (T-cells). Peripheral T-cell lymphoma (PTCL) is a group of rare and usually aggressive (fast-growing) Non-Hodgkin’s Lymphomas (NHL) that develops from mature T-cells.

As per the latest report of DelveInsight, PTCL comprises about 10-15% of all NHL cases in the United States. PTCL is classified into 4 main categories namely: Nodal, Extranodal, Cutaneous and Leukemic. Out of all, Nodal PTCL is the most common type of Peripheral T-cell Lymphoma. In 2016, the US accounted for more than 7000 cases of PTCL, and according to the estimations made by professionals, this number will exceed 10000 cases by the year 2025 in the US alone.

According to “Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology, and Market Forecast-2025” patients suffering from PTCL in the US are now diagnosed at the initial stages due to the improvement in diagnostic techniques and a better understanding of the disease. Some of the marketed drugs for PTCL are Belinostat (from Spectrum Pharmaceuticals), Romidepsin (from Celgene Corporation), Pralatrexate (from Spectrum Pharmaceuticals) and many others are leading the PTCL market. The PTCL therapeutics market in 7MM’s is expected to grow at a CAGR of 8.3% by 2025, due to the increasing prevalence of the disease worldwide. There are unmet needs for the relapsed/refractory cases and the patients suffering from rarer subtypes of PTCL due to very less number of such incidents.

This report provides detailed information about the global market scenario, epidemiology and geography wise incident cases of PTCL. Competitive insights and data on marketed products and emerging therapies are also provided for better understanding of the PTCL market. The report also identifies the possible drivers and barriers. Highly detailed information about the PTCL domain will help to gain a strategic advantage over the other key players in the market.

Companies covered include Celgene Corporation, Spectrum Pharmaceuticals, Kyowa Hakko Kirin, Seattle genetics and Roche.

Reasons to Purchase:
- develop business strategies by understanding trends shaping and driving the PTCL market;
- understand competitive landscape in the PTCL market;
- become informed about the key market drivers and barriers;
- organize sales and marketing efforts by identifying the best opportunities for PTCL in the US, Europe (Germany, Spain, Italy, France and the UK) and Japan;
- develop strategies that will help in getting ahead of competitors;
- get a detailed analysis of the global historical and forecasted Peripheral T-Cell Lymphoma (PTCL) market scenario across 7 major country markets;
etc.

Many other market research studies can be found at https://marketpublishers.com

About the company:

TD The Market Publishers, Ltd. gives access to an extensive collection of topical research reports investigating different markets. It supplies its customers with periodical publications, databooks, on-line subscriber services and much more. The company's report database is updated daily. Market Publishers is always ready to supply updated information on the target markets to its customers. Market Publishers' online research reports hypermarket includes over 1.5 million publications, so it is able to satisfy demand of the most exacting clients.